| NCT05436535 | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 2022-11-21 | PHASE4 |
| NCT04244006 | University Hospital, Toulouse|MedSharing | Netherton Syndrome | 2020-07-23 | PHASE2|PHASE3 |
| NCT07574294 | Azienda Ulss 2 Marca Trevigiana | Asthma|Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2025-06-16 | |
| NCT06193434 | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Participants|Atopic Dermatitis Patients | 2024-01-05 | PHASE1 |
| NCT04287608 | Regeneron Pharmaceuticals|Sanofi | Conjunctivitis|Atopic Dermatitis | 2021-03-10 | |
| NCT01639040 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2012-07 | PHASE2 |
| NCT06937788 | Technische Universit?t Dresden | Atopic Dermatitis | 2021-08-02 | |
| NCT04988022 | Icahn School of Medicine at Mount Sinai|Regeneron Pharmaceuticals|Sanofi | Keloid | 2021-05-25 | PHASE4 |
| NCT07049978 | Medical University of Vienna | NSAID-Induced Asthma|NSAIDs Hypersensitivity|Chronic Rhinosinusitis (CRS)|Asthma Bronchiale|Nasal Polyposis | 2025-07-01 | |
| NCT05203380 | Regeneron Pharmaceuticals|Sanofi | Moderate-to-severe Atopic Dermatitis | 2022-01-27 | |
| NCT05866562 | Icahn School of Medicine at Mount Sinai | Alopecia Areata | 2024-07-11 | PHASE2 |
| NCT03428646 | Regeneron Pharmaceuticals|Sanofi | Dermatitis, Atopic | 2018-04-06 | |
| NCT06192563 | Sanofi | Dermatitis Atopic | 2023-11-30 | |
| NCT06188871 | University of Rochester | Chronic Rhinosinusitis With Nasal Polyps | 2024-06-01 | PHASE4 |
| NCT03720470 | Pfizer | Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases | 2018-10-29 | PHASE3 |
| NCT05649579 | Peking University First Hospital|Ruijin Hospital|Chinese Academy of Medical Sciences|West China Hospital|Second Xiangya Hospital of Central South University|Shandong Provincial Institute of Dermatology and Venereology | Bullous Pemphigoid | 2022-09-01 | |
| NCT02948959 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2017-04-21 | PHASE3 |
| NCT07053423 | Sanofi|Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease | 2025-09-22 | PHASE4 |
| NCT06393946 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyposis | 2023-10-20 | |
| NCT05731128 | Sanofi|Regeneron Pharmaceuticals | Colitis Ulcerative | 2023-01-12 | PHASE2 |
| NCT05967884 | Ottawa Hospital Research Institute|Ontario Institute for Cancer Research | Breast Cancer | 2023-08-04 | PHASE2 |
| NCT07151508 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Neterton Syndrome | 2023-12-19 | |
| NCT05787678 | Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau | Asthma; Eosinophilic | 2023-10-01 | |
| NCT04743791 | Sally E. Wenzel MD | Asthma | 2022-10-17 | PHASE4 |
| NCT03387852 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2018-03-12 | PHASE2 |
| NCT05991323 | Sanofi|Regeneron Pharmaceuticals | Prurigo Nodularis | 2023-12-12 | |
| NCT04895423 | National Medical Research Center for Children´s Health, Russian Federation | Atopic Dermatitis | 2021-11-25 | PHASE4 |
| NCT06461897 | AbbVie | Atopic Dermatitis | 2024-08-19 | PHASE3 |
| NCT03912259 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2018-12-19 | PHASE3 |
| NCT05976386 | Sanofi|Regeneron Pharmaceuticals | Healthy Volunteers | 2021-06-08 | PHASE1 |
| NCT04033367 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2019-08-22 | PHASE4 |
| NCT06477653 | National Institute of Allergy and Infectious Diseases (NIAID) | Hypereosinophilic Syndrome | 2025-02-05 | PHASE2 |
| NCT06868212 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria (CSU) | 2025-07-11 | PHASE3 |
| NCT06389136 | AbbVie | Atopic Dermatitis | 2024-06-14 | PHASE3 |
| NCT04996485 | National Medical Research Center for Children´s Health, Russian Federation | Congenital Ichthyosis | 2021-03-01 | PHASE4 |
| NCT06012448 | University of Michigan|Regeneron Pharmaceuticals | Dermal Hypersensitivity Reaction | 2023-10-02 | PHASE4 |
| NCT03983460 | Association pour la Recherche Clinique et Immunologique | Atopic Dermatitis | 2020-03-09 | NA |
| NCT03782532 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2019-01-25 | PHASE3 |
| NCT03930732 | Sanofi|Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease | 2019-04-15 | PHASE3 |
| NCT07309614 | Université de Sherbrooke|Sanofi|University of Oxford|The University of Western Australia|Regeneron Pharmaceuticals|Fonds de la Recherche en Santé du Québec|Association Pulmonaire du Quebec | Asthma Control | 2026-01-29 | PHASE3 |
| NCT06687967 | Sanofi|Regeneron Pharmaceuticals | Lichen Simplex Chronicus | 2024-11-28 | PHASE3 |
| NCT05976360 | Sanofi|Regeneron Pharmaceuticals | Healthy Volunteer | 2014-11-02 | PHASE1 |
| NCT06169527 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2023-11-28 | |
| NCT04442256 | Medical University of Vienna | AERD - Aspirin Exacerbated Respiratory Disease | 2020-06-01 | PHASE4 |
| NCT06352073 | University of North Carolina, Chapel Hill|Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis|EoE | 2024-05-16 | PHASE4 |
| NCT06087627 | Sanofi | Prurigo Nodularis | 2023-12-27 | |
| NCT04430179 | University of South Florida | Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis | 2020-12-17 | PHASE2 |
| NCT05526521 | Sanofi | Chronic Spontaneous Urticaria | 2022-08-25 | PHASE3 |
| NCT05680298 | Sanofi | Atopic Dermatitis | 2023-02-22 | PHASE4 |
| NCT03694158 | Boston Children´s Hospital|National Institute of Allergy and Infectious Diseases (NIAID)|Regeneron Pharmaceuticals|HealthBeacon Plc|Merck Sharp & Dohme LLC|Sanofi | Asthma | 2021-09-08 | PHASE4 |
| NCT04362501 | Johns Hopkins University|Regeneron Pharmaceuticals | Chronic Sinusitis | 2020-10-15 | PHASE2 |
| NCT01979016 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis (AD) | 2013-12-31 | PHASE2 |
| NCT07027527 | Apogee Therapeutics, Inc. | Atopic Dermatitis | 2025-06-04 | PHASE1 |
| NCT04296864 | Andover Eye Associates|Statistics & Data Corporation|Regeneron Pharmaceuticals | Atopic Keratoconjunctivitis | 2020-02-10 | PHASE2 |
| NCT01920893 | Sanofi|Regeneron Pharmaceuticals | Nasal Polyps | 2013-08 | PHASE2 |
| NCT05642208 | Nantes University Hospital | Atopic Dermatitis|Eczema, Atopic | 2023-03-08 | PHASE4 |
| NCT02260986 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2014-09 | PHASE3 |
| NCT06743581 | Centre hospitalier de l´Université de Montréal (CHUM) | Non-Small Cell Lung Cancer|Immunotherapy|Neoadjuvant Therapy | 2025-02-01 | NA |
| NCT07112378 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis (EoE) | 2025-11-10 | PHASE3 |
| NCT02395133 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2015-03-25 | PHASE3 |
| NCT07334496 | Gan & Lee Pharmaceuticals. | Biosimilarity | 2026-03-09 | PHASE1 |
| NCT03293030 | University of California, San Francisco|Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis|Atopic Dermatitis Eczema|Eczema|Atopic Dermatitis and Related Conditions | 2018-10-22 | PHASE4 |
| NCT06637306 | Rima Patel | Locally Advanced Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer | 2025-03-05 | EARLY_PHASE1 |
| NCT04380038 | University of Virginia|Regeneron Pharmaceuticals | Asthma | 2022-05-01 | PHASE4 |
| NCT06665971 | University of California, San Diego|Regeneron Pharmaceuticals | Eosinophilic Esophagitis (EoE) | 2024-11-10 | PHASE4 |
| NCT02277743 | Regeneron Pharmaceuticals|Sanofi | Dermatitis, Atopic | 2014-10 | PHASE3 |
| NCT05372003 | Mayo Clinic | Atopic Dermatitis | 2022-08-09 | EARLY_PHASE1 |
| NCT04596189 | Centre hospitalier de l´Université de Montréal (CHUM) | Chronic Rhinosinusitis With Nasal Polyps | 2021-05-25 | PHASE4 |
| NCT04678856 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis Without Nasal Polyps|Sinusitis|Chronic Sinusitis|Sinus Disorder|Respiratory Disorder | 2020-12-02 | PHASE3 |
| NCT06398873 | Medical University of Vienna | Chronic Rhinosinusitis With Nasal Polyps|Chronic Rhinosinusitis Without Nasal Polyps | 2024-06-06 | |
| NCT04456673 | Sanofi|Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease | 2020-07-06 | PHASE3 |
| NCT03560466 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2018-06-21 | PHASE3 |
| NCT04718870 | Sanofi|Regeneron Pharmaceuticals | Dermatitis Atopic | 2021-02-19 | PHASE4 |
| NCT02647086 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2015-12 | PHASE1 |
| NCT05976373 | Sanofi|Regeneron Pharmaceuticals | Healthy Volunteers | 2015-01-05 | PHASE1 |
| NCT02414854 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2015-04-27 | PHASE3 |
| NCT07352566 | University of California, San Francisco | Psoriasis|Atopic Dermatitis | 2026-01-01 | PHASE4 |
| NCT05649098 | Northwestern University | Skin Diseases | 2023-06-12 | EARLY_PHASE1 |
| NCT01548404 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2012-04 | PHASE2 |
| NCT03633617 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis | 2018-09-24 | PHASE3 |
| NCT04203797 | Regeneron Pharmaceuticals | Asthma | 2020-07-16 | PHASE4 |
| NCT05906706 | Regeneron Pharmaceuticals|Sanofi | Bullous Pemphigoid | | |
| NCT01949311 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2013-10-10 | PHASE3 |
| NCT02379052 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis | 2015-05-12 | PHASE2 |
| NCT05042258 | Northwestern University|Regeneron Pharmaceuticals | Atopic Dermatitis|Sleep Disturbance | 2024-08-12 | PHASE4 |
| NCT05246267 | Montefiore Medical Center|Regeneron Pharmaceuticals|Mayo Clinic | Chronic Rhinosinusitis With Nasal Polyps | 2022-02-15 | |
| NCT07330934 | Innovent Biologics (Suzhou) Co. Ltd. | Atopic Dermatitis | 2025-12-31 | PHASE2 |
| NCT03112577 | Regeneron Pharmaceuticals|Sanofi | Asthma, Allergic | 2017-06-15 | PHASE1 |
| NCT06415175 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2024-11-14 | |
| NCT05831176 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Gastritis (EoG)|Eosinophilic Duodenitis (EoD)|Eosinophilic Gastrointestinal Disease (EGID)|Eosinophilic Gastroenteritis | 2023-05-03 | PHASE2 |
| NCT05624112 | Sanofi | Atopic Dermatitis|Dermatitis Atopic | 2022-11-25 | PHASE4 |
| NCT04256759 | Mayo Clinic|Regeneron Pharmaceuticals | Pruritus | 2020-09-01 | PHASE2 |
| NCT03682770 | Regeneron Pharmaceuticals|Sanofi|Aimmune Therapeutics, Inc. | Peanut Allergy | 2018-10-03 | PHASE2 |
| NCT01385657 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2011-07-31 | PHASE1 |
| NCT03992417 | Sanofi|Regeneron Pharmaceuticals | Dermatitis Atopic | 2019-06-11 | |
| NCT02755649 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2016-01-31 | PHASE3 |
| NCT04345367 | Pfizer | Atopic Dermatitis | 2020-06-11 | PHASE3 |
| NCT06101095 | Sanofi|Regeneron Pharmaceuticals | Eosinophilic Oesophagitis | 2023-11-29 | PHASE4 |
| NCT05268107 | University of Michigan|Regeneron Pharmaceuticals | Atopic Dermatitis | 2023-01-25 | PHASE4 |
| NCT02407756 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2015-03-31 | PHASE2 |
| NCT03736967 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2018-11-12 | PHASE2 |
| NCT03749148 | Charite University, Berlin, Germany|Sanofi|Proinnovera GmbH | Cholinergic Urticaria | 2018-12-10 | PHASE2 |
| NCT03738397 | AbbVie | Atopic Dermatitis | 2019-02-21 | PHASE3 |
| NCT04442269 | Regeneron Pharmaceuticals|Sanofi | Allergic Bronchopulmonary Aspergillosis | 2020-09-15 | PHASE2 |
| NCT06226610 | Akron Children´s Hospital|Regeneron Pharmaceuticals|Ohio State University | Pruritis | 2024-11-21 | PHASE2 |
| NCT05575037 | Brigham and Women´s Hospital|National Institute of Allergy and Infectious Diseases (NIAID) | Nasal Polyps|Asthma, Aspirin-Induced|Aspirin-Exacerbated Respiratory Disease|Aspirin-Sensitive Asthma With Nasal Polyps | 2023-08-01 | PHASE2 |
| NCT03054428 | Regeneron Pharmaceuticals|Sanofi | Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic | 2017-03-21 | PHASE3 |
| NCT02528214 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2015-10-15 | PHASE3 |
| NCT06705387 | University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Eosinophilic Esophagitis | 2024-12-23 | PHASE2 |
| NCT06116526 | Johns Hopkins University|Doris Duke Charitable Foundation | Atopic Dermatitis | 2024-04-01 | PHASE4 |
| NCT06385236 | University of California, San Diego|Mayo Clinic|Yale University|University of Arizona|Harvard University|Brigham and Women´s Hospital|National Heart, Lung, and Blood Institute (NHLBI) | Moderate to Severe Asthma | 2024-02-19 | PHASE4 |
| NCT07358234 | Mayo Clinic|Vanderbilt University Medical Center | Eosinophilic Esophagitis (EoE) | 2026-02-04 | EARLY_PHASE1 |
| NCT04022447 | Assistance Publique - H?pitaux de Paris | Severe Asthma | 2018-08-10 | |
| NCT06851403 | Guangzhou Institute of Respiratory Disease | Asthma in Children | 2022-01-30 | |
| NCT02210780 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2014-08-05 | PHASE2 |
| NCT04173442 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis (AD)|Asthma | 2018-10-24 | |
| NCT05601882 | AbbVie | Atopic Dermatitis | 2022-11-28 | PHASE3 |
| NCT04520308 | Eric Simpson|Regeneron Pharmaceuticals | Atopic Dermatitis|AD|Eczema | 2020-09-01 | PHASE4 |
| NCT04512339 | University Medical Center Groningen|Genzyme, a Sanofi Company | Hand Eczema | 2020-08-01 | PHASE2 |
| NCT04394351 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis (EoE) | 2020-09-01 | PHASE3 |
| NCT06556264 | Dr. Andrew Thamboo, MD|Sanofi | Chronic Rhinosinusitis With Nasal Polyps|Asthma | 2024-08 | PHASE4 |
| NCT07467564 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2026-02-24 | |
| NCT05551793 | Emma Guttman|Regeneron Pharmaceuticals | Alopecia Areata | 2023-04-10 | PHASE2 |
| NCT04998604 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyps|Asthma | 2021-09-27 | PHASE4 |
| NCT03861455 | University Hospital, Toulouse | Chronic Hand Eczema | 2019-07-15 | PHASE2 |
| NCT03620747 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2018-08-30 | PHASE3 |
| NCT05529784 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Chronic Rhinosinusitis With Nasal Polyps | 2021-10-06 | |
| NCT06572228 | Regeneron Pharmaceuticals|Sanofi | Asthma | 2024-08-26 | PHASE4 |
| NCT03020810 | Sally E. Wenzel MD | Asthma | | |
| NCT06191315 | Sanofi|Regeneron Pharmaceuticals | Wheezing|Asthma | 2024-01-03 | PHASE3 |
| NCT04400318 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2020-06-20 | PHASE4 |
| NCT05263206 | Sanofi | Pruritus | 2022-02-15 | PHASE3 |
| NCT03345914 | Regeneron Pharmaceuticals|Sanofi | Dermatitis, Atopic | 2017-11-17 | PHASE3 |
| NCT03679676 | Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)|Food Allergy Research & Education|Harvard School of Public Health (HSPH) | Hypersensitivity|Food Allergy|Hypersensitivity, Food|Peanut Hypersensitivity|Peanut Allergy | 2020-02-05 | PHASE2 |
| NCT06892704 | Northwestern University|Sanofi | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)|Smell Loss | 2025-05-01 | |
| NCT05247866 | Children´s Hospital of Philadelphia|Regeneron Pharmaceuticals|Genzyme, a Sanofi Company | Eosinophilic Esophagitis | 2022-06-16 | PHASE4 |
| NCT03675022 | Brigham and Women´s Hospital | Sleep Apnea|Rhinosinusitis Chronic | 2018-08-15 | EARLY_PHASE1 |
| NCT03411837 | Northwestern University | Atopic Dermatitis | 2017-10-16 | |
| NCT06088771 | Icahn School of Medicine at Mount Sinai | Non-Small Cell Lung Cancer | 2024-03-08 | PHASE1|PHASE2 |
| NCT04878770 | Erasmus Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development | Dermatitis, Atopic | 2021-08-16 | NA |
| NCT02898454 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 2016-11-28 | PHASE3 |
| NCT05983068 | Sanofi|Regeneron Pharmaceuticals | Dermatitis Atopic | 2024-02-22 | PHASE4 |
| NCT06693531 | Regeneron Pharmaceuticals|Sanofi | Eosinophilic Esophagitis (EoE) | 2024-11-22 | |
| NCT05265234 | OptiSkin Medical|Regeneron Pharmaceuticals | Eczema|Atopic Dermatitis | 2022-03-01 | PHASE4 |
| NCT05036733 | University of Michigan|Regeneron Pharmaceuticals | Asthma | 2022-02-22 | PHASE4 |
| NCT04791319 | Janssen Research & Development, LLC | Dermatitis, Atopic | 2021-05-03 | PHASE2 |
| NCT06683261 | Universitaire Ziekenhuizen KU Leuven | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)|Chronic Rhinosinusitis (CRS) | 2022-09-23 | |
| NCT03678545 | Children´s Hospital Medical Center, Cincinnati|Regeneron Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID) | Eosinophilic Gastritis|Eosinophilic Gastroenteritis | 2021-05-15 | PHASE2 |
| NCT07187089 | Regeneron Pharmaceuticals|Sanofi | Severe Atopic Dermatitis (AD) | 2025-11-11 | PHASE4 |
| NCT05590585 | Regeneron Pharmaceuticals|Sanofi | Moderate-to-Severe Atopic Dermatitis|Atopic Eczema | 2023-01-11 | PHASE4 |
| NCT04600362 | Technical University of Munich|University Hospital Munich | Nummular Eczema | 2021-03-30 | PHASE2 |
| NCT05049122 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyps | 2021-10-22 | PHASE4 |
| NCT06881251 | Janssen Research & Development, LLC | Dermatitis, Atopic | 2025-02-26 | PHASE2 |
| NCT04550962 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2020-11-02 | |
| NCT06818019 | University Hospital, Toulouse | Severe Asthma | 2025-04-02 | PHASE4 |
| NCT06631677 | Regeneron Pharmaceuticals | Food Allergy | | |
| NCT06293053 | Sanofi|Regeneron Pharmaceuticals | Prurigo Nodularis | 2024-05-15 | PHASE3 |
| NCT05535738 | Wei-Che Ko | Skin Inflammation|Allergic Contact Dermatitis | 2022-11-15 | PHASE2|PHASE3 |
| NCT06750471 | Madigan Army Medical Center|Tripler Army Medical Center|Fort Belvoir Community Hospital|William Beaumont Army Medical Center | Nasal Polyps|Sinusitis|Chronic Disease | 2021-10-14 | PHASE4 |
| NCT07448363 | Caja Costarricense de Seguro Social | Atopic Dermatitis|Atopic Dermatitis (AD)|Atopic Dermatitis (Eczema)|Atopic Dermatitis Patients|Atopic Dermatitis + Eczema|Atopic Dermatitis, Unspecified | 2026-05 | |
| NCT04920916 | University of Virginia|The Paul Manning Foundation|Virginia Catalyst | COVID-19 | 2021-05-25 | PHASE2 |
| NCT07399067 | Innovent Biologics (Suzhou) Co. Ltd. | Atopic Dermatitis | 2026-02-06 | PHASE2 |
| NCT05878093 | Sanofi | Chronic Rhinosinusitis With Nasal Polyps | 2023-05-16 | PHASE3 |
| NCT06509243 | Medical University of Silesia | Atopic Dermatitis | 2023-02-10 | NA |
| NCT04200755 | University of Cologne | Localized Scleroderma | 2020-05-19 | PHASE2 |
| NCT05331755 | Gert-Jan Braunstahl|Genzyme, a Sanofi Company | Severe Asthma | 2021-04-01 | |
| NCT05720325 | The University of Texas Health Science Center at San Antonio|National Institute of Allergy and Infectious Diseases (NIAID)|Regeneron Pharmaceuticals | Asthma, Allergic | 2023-03-29 | PHASE2 |
| NCT05097287 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2021-12-16 | PHASE4 |
| NCT07276425 | UMC Utrecht|Sanofi | Prurigo Nodularis (PN) | 2025-06-01 | |
| NCT04183335 | Sanofi|Regeneron Pharmaceuticals | Neurodermatitis | 2019-12-12 | PHASE3 |
| NCT03749135 | Charite University, Berlin, Germany|Sanofi|Proinnovera GmbH | Chronic Spontaneous Urticaria|Recurrent Angioedema | 2018-11-12 | PHASE2 |
| NCT04202679 | Sanofi|Regeneron Pharmaceuticals | Neurodermatitis | 2020-01-16 | PHASE3 |
| NCT02912468 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 2016-12-05 | PHASE3 |
| NCT04358224 | Jonathan A. Bernstein, MD | Atopic Dermatitis|Eczema | 2020-09-01 | PHASE4 |
| NCT06687980 | Sanofi|Regeneron Pharmaceuticals | Lichen Simplex Chronicus | 2024-11-25 | PHASE3 |
| NCT03558997 | Regeneron Pharmaceuticals|Sanofi | Allergic Rhinitis | 2018-06-07 | PHASE2 |
| NCT06695897 | Sanofi|Regeneron Pharmaceuticals | Eosinophilic Esophagitis | 2024-12-02 | |
| NCT07025200 | Medical University of Vienna | Asthma | 2023-02-16 | |
| NCT07502534 | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Volunteers | 2026-04-20 | PHASE1 |
| NCT06004986 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Prothya Biosolutions | Atopic Dermatitis|Atopic Dermatitis Eczema | 2023-08-14 | PHASE4 |
| NCT04681729 | Sanofi|Regeneron Pharmaceuticals | Cold Urticaria | 2020-12-10 | PHASE3 |
| NCT03793608 | Regeneron Pharmaceuticals|Sanofi | Peanut Allergy | 2019-03-12 | PHASE2 |
| NCT04678882 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2021-01-15 | PHASE3 |
| NCT03936335 | Regeneron Pharmaceuticals|Sanofi | Adverse Pregnancy Outcomes|Atopic Dermatitis | 2019-09-30 | |
| NCT02134028 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2014-08-05 | PHASE3 |
| NCT06465732 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Atopic Dermatitis | 2025-01 | PHASE4 |
| NCT07316114 | Sanofi|Regeneron Pharmaceuticals | Chronic Spontaneous Urticaria | 2026-03-18 | |
| NCT01859988 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2013-05 | PHASE2 |
| NCT05790330 | King´s College London|Guy´s and St Thomas´ NHS Foundation Trust | Atopic Dermatitis | 2023-03-10 | |
| NCT01854047 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2013-06 | PHASE2 |
| NCT06461949 | National Institute on Deafness and Other Communication Disorders (NIDCD) | Allergic Fungal Rhinosinusitis (AFRS)|Chronic Rhinosinusitis (CRS)|Asthma|Nasal Polyps | 2024-07-17 | PHASE3 |
| NCT04823130 | Sanofi|Regeneron Pharmaceuticals | Dermatitis Atopic | 2021-04-22 | PHASE4 |
| NCT04869436 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s|Mount Sinai Hospital, Canada | Chronic Rhinosinusitis With Nasal Polyps|Olfactory Disorder | 2021-07-19 | PHASE4 |
| NCT05964465 | Medical University of South Carolina | Chronic Rhinosinusitis With Nasal Polyps | 2023-08-10 | PHASE4 |
| NCT04148352 | Andrew J Long, PharmD|Robert Levin Charitable Fund|Regeneron Pharmaceuticals | Allergies Food Milk | 2021-10-18 | PHASE2 |
| NCT06234761 | University Hospital, Ghent|Sanofi | Pathophysiology | 2024-01-02 | |
| NCT03667014 | University of California, San Francisco|Regeneron Pharmaceuticals | Atopic Dermatitis|Atopic Dermatitis Eczema | 2018-11-01 | PHASE4 |
| NCT05013450 | Thomas Marron | Metastatic Non-small Cell Lung Cancer | 2021-09-10 | PHASE1|PHASE2 |
| NCT07257835 | Children´s Hospital of Fudan University | Eosinophilic Gastrointestinal Disorders (EGIDs) | 2025-01-01 | |
| NCT03595488 | Rochester General Hospital | Aspirin-exacerbated Respiratory Disease | 2018-09-05 | PHASE2 |
| NCT04180488 | Sanofi|Regeneron Pharmaceuticals | Chronic Spontaneous Urticaria | 2019-12-11 | PHASE3 |
| NCT02277769 | Regeneron Pharmaceuticals|Sanofi | Dermatitis, Atopic | 2014-11-30 | PHASE3 |
| NCT04776694 | Regeneron Pharmaceuticals | Type 2 Inflammatory Disorders | | |
| NCT01312961 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2011-03 | PHASE2 |
| NCT04665141 | Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinic of Barcelona|Hospital Regional de Malaga | Asthma | 2021-04-07 | |
| NCT03359356 | Icahn School of Medicine at Mount Sinai|Rockefeller University|Regeneron Pharmaceuticals|Sanofi | Alopecia Areata | 2018-01-09 | PHASE2 |
| NCT05128383 | Beth Israel Deaconess Medical Center|Regeneron Pharmaceuticals | Keloid | 2023-01-13 | PHASE2 |
| NCT03050151 | Regeneron Pharmaceuticals|Sanofi | Atopic Disorders|Eczema, Atopic | 2017-02-28 | PHASE1 |
| NCT03346434 | Regeneron Pharmaceuticals|Sanofi | Dermatitis, Atopic | 2017-11-30 | PHASE2|PHASE3 |
| NCT05942222 | Rigshospitalet, Denmark | Chronic Rhinosinusitis With Nasal Polyps|Asthma; Eosinophilic|Eosinophilia | 2023-04-27 | PHASE4 |
| NCT02612454 | Regeneron Pharmaceuticals|Sanofi | Atopic Dermatitis | 2015-10-15 | PHASE3 |
| NCT07277322 | Dan Feng|Coherus Oncology, Inc. | Metastatic Colorectal Cancer|Liver Metastases | 2026-06-01 | PHASE1|PHASE2 |
| NCT04206553 | Regeneron Pharmaceuticals|Sanofi | Bullous Pemphigoid | 2020-10-28 | PHASE2|PHASE3 |
| NCT03358693 | Prof. Dr. Stephan Weidinger | Atopic Dermatitis|Psoriasis | 2017-01-20 | |
| NCT05858619 | University of California, San Francisco | Atopic Dermatitis | 2023-02-01 | PHASE4 |
| NCT07052396 | Sanofi|Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease (COPD) | 2025-07-01 | |
| NCT04447417 | Sanofi|Regeneron Pharmaceuticals | Atopic Dermatitis | 2020-07-16 | PHASE4 |
| NCT02573233 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2016-01-27 | PHASE2 |
| NCT04684524 | Sanofi|Regeneron Pharmaceuticals | Allergic Fungal Rhinosinusitis | 2020-12-01 | PHASE3 |
| NCT05545072 | Emory University|Sanofi | Allergic Fungal Rhinosinusitis | 2023-10-26 | PHASE3 |
| NCT06369467 | Regeneron Pharmaceuticals | Food Allergy | 2024-05-17 | PHASE1 |
| NCT04417894 | Regeneron Pharmaceuticals|Sanofi | Moderate to Severe Atopic Hand and Foot Dermatitis | 2021-04-14 | PHASE3 |
| NCT07091175 | National University Hospital, Singapore|National Medical Research Council (NMRC), Singapore|KK Women´s and Children´s Hospital|National University of Singapore | Nephrotic Syndrome in Children|Nephrotic Syndrome Steroid-Dependent | 2025-11-27 | PHASE2 |
| NCT05094570 | University of Virginia|Regeneron Pharmaceuticals | Nasal Polyps|Staphylococcus Aureus | 2022-09-01 | PHASE4 |
| NCT03935971 | Brigham and Women´s Hospital|Regeneron Pharmaceuticals | Allergic Contact Dermatitis | 2019-12-18 | PHASE4 |
| NCT01484600 | Regeneron Pharmaceuticals|Sanofi | Healthy | 2011-12 | PHASE1 |
| NCT01537653 | Sanofi|Regeneron Pharmaceuticals | Healthy | 2012-03 | PHASE1 |
| NCT01537640 | Sanofi|Regeneron Pharmaceuticals | Healthy | 2012-02 | PHASE1 |
| NCT01259323 | Regeneron Pharmaceuticals|Sanofi | Dermatitis | 2010-12 | PHASE1 |
| NCT01015027 | Regeneron Pharmaceuticals|Sanofi | Healthy | 2009-10 | PHASE1 |
| NCT04502862 | Sanofi|Regeneron Pharmaceuticals | Asthma | 2020-08-10 | PHASE4 |